Comprehensive Review Maps FDA-Approved and Emerging Obesity Treatments

Obesity is a complex, chronic disease affecting millions globally, significantly increasing the risk of conditions like type 2 diabetes, cardiovascular disease, and certain cancers. While lifestyle interventions are foundational, many individuals require additional support through pharmacotherapy. Despite the growing arsenal of medications, clinicians and patients often face challenges navigating the rapidly evolving landscape of available and pipeline treatments. This review addresses the critical need for a current, comprehensive overview of both FDA-approved and investigational medical therapies for obesity, synthesizing their mechanisms, efficacy, and safety profiles.

The review highlighted a significant evolution in obesity pharmacotherapy, with newer agents demonstrating superior efficacy. GLP-1 receptor agonists (e.g., semaglutide) consistently showed substantial weight loss, with patients achieving an average of 15-17% body weight reduction over 68 weeks compared to placebo. Dual GLP-1/GIP agonists like tirzepatide exhibited even greater efficacy, often leading to 20-25% weight loss in clinical trials. Investigational therapies, including amylin analogs and melanocortin-4 receptor agonists, are showing promising early results in preclinical and Phase I/II human studies, with some demonstrating 10-12% weight loss in initial trials. > The most impactful finding was the clear trend towards multi-hormonal agonists achieving superior weight loss outcomes, with tirzepatide showing up to a 22.5% mean weight reduction in pivotal clinical trials, significantly surpassing older generation medications (e.g., orlistat's 3-5% reduction). Safety profiles varied, with gastrointestinal side effects (nausea, vomiting) being common across most effective agents but generally manageable and transient, leading to low discontinuation rates, typically below 5-10%.